Kymera Stock Soars on Breakthrough Eczema Drug Results
Kymera Therapeutics (KYMR) shares surge after Phase 1b trial shows KT-621 oral pill achieves Dupixent-like efficacy in treating moderate to severe eczema with favorable safety profile.
/ 1 item
#KYMR↓